Previous 10 | Next 10 |
Cardiovascular diseases are costing the U.S. $1 billion per day in medical fees and productivity losses The number of heart attacks is increasing on an annual basis, highlighting the importance of early detection technology Zenosense is developing a handheld device that could significan...
Healthcare technology company Zenosense (OTC: ZENO) this morning announced that the company has started trading on the OTC Markets Group OTCQB “Venture Market”. Known as an established public market by the U.S. Securities and Exchange Commission (“SEC”), the OTCQB i...
VALENCIA, SPAIN, July 10, 2018 (GLOBE NEWSWIRE) -- Zenosense, Inc. (OTCQB: ZENO, "Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held device for the early detection of heart attack at the Point of...
Healthcare technology company Zenosense (OTC: ZENO), through its joint venture ownership of MIDS Medical Limited (“MML”), is developing “MIDS”, a nano-magnetic detection technology to allow true laboratory accuracy at the point-of-care (“POC”). A recen...
Joint Venture MIDS technology doubles detection capability in second testing round MIDS Technology aims to provide ambulance personnel, ERs with a fast, easy, low-cost and powerful device to diagnose potential cardiac symptoms Chest pain diagnosis is one of the most common challenges fo...
Healthcare technology company Zenosense (OTC: ZENO) is currently developing its MIDS Cardiac handheld diagnostic technology to provide rapid cardiac biomarker tests in emergency settings. A recent article discussing the company reads: “ MIDS goes beyond the optical technology used by mo...
New York, New York--(Newsfile Corp. - June 28, 2018) - NetworkNewsAudio announces the Audio Press Release (APR) titled "Diagnostics Play Critical Role in Medical Sector," featuring Zenosense (OTC Pink: ZENO). To hear the NetworkNewsAudio version, visit http://nnw.fm/kqyU7 To read th...
POC devices speed up triage, diagnosis and treatment of patients MIDS Cardiac™ is being developed to detect the biomarker troponin I or T for suspected heart attack within 3 minutes, as opposed to often taking 60 minutes in central laboratories Global cardiac biomarkers market ex...
NEW YORK, June 27, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Zenosense (OTC:ZENO), a client of NNW and healthcare technology developer focused...
NetworkNewsWire Editorial Coverage : Diagnostic devices are a crucial part of the medical technology sector, and many companies are pressing forward with work in this area. Zenosense, Inc. (OTC: ZENO) ( ZENO Profile ) has just announced breakthrough quantitative test results for its MIDS Ca...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK , June 5, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lists of downgrades from its respective OTCQX® and OTCQB® markets and Caveat Emptor Desig...
VALENCIA, SPAIN, March 20, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Zenosense, Inc. (OTCQB: ZENO, "Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection o...
Agreement signed with third party investor to fund up to $1.2 million to support next crucial development phase of MIDS Cardiac POC diagnostic device Patented MIDS technology has successfully detected commercial assay beads at a level approximately four times better than the threshold adv...